|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits viral replication
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1993
gptkb:FDA
|
|
gptkbp:brand
|
Flumadine
|
|
gptkbp:class
|
adamantane derivatives
|
|
gptkbp:clinical_trial
|
Phase III
prophylaxis of influenza
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to rimantadine
|
|
gptkbp:developed_by
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:dosage_form
|
100 mg twice daily
|
|
gptkbp:duration
|
5 to 7 days
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rimantadine
|
|
gptkbp:ingredients
|
C12 H21 N
|
|
gptkbp:interacts_with
|
gptkb:beer
anticholinergic drugs
|
|
gptkbp:is_atype_of
|
J05 A B01
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_effective_against
|
gptkb:influenza_B
|
|
gptkbp:is_used_for
|
treatment of influenza A
|
|
gptkbp:lifespan
|
25 hours
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
oral bioavailability 70%
|
|
gptkbp:research_focus
|
antiviral resistance
|
|
gptkbp:side_effect
|
anxiety
dizziness
fatigue
headache
nausea
insomnia
constipation
dry mouth
|
|
gptkbp:type_of
|
19982-08-2
|
|
gptkbp:water_resistance
|
viral mutations
|
|
gptkbp:bfsParent
|
gptkb:amantadine
|
|
gptkbp:bfsLayer
|
6
|